<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629770</url>
  </required_header>
  <id_info>
    <org_study_id>VZR_2014-3</org_study_id>
    <nct_id>NCT02629770</nct_id>
  </id_info>
  <brief_title>Clindamycin-rifampin Drug Interaction in the Treatment of Bone and Joint Infections</brief_title>
  <acronym>CLIRIFA</acronym>
  <official_title>Clindamycin-Rifampin Interactions: Effect of Rifampin's Enzyme-induction (Cytochrome P450 3A4/3A5) on Plasma Clindamycin Concentrations, With Clindamycin Given Intravenously and Orally to Treat Bone-and-joint Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Diaconesses Croix Saint-Simon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Diaconesses Croix Saint-Simon</source>
  <brief_summary>
    <textblock>
      Treatment of bone and joint infections remains difficult and variable according to centres&#xD;
      and countries. Clindamycin given intravenously and followed by an oral route is recommended&#xD;
      for the treatment of staphylococcal, streptococcal and anaerobes bone and joint infections by&#xD;
      the French Society for Infectious Diseases. For staphylococcal bone and implant infections,&#xD;
      rifampin is a major drug, as it remains active in bacterial biofilm and on quiescent&#xD;
      staphylococci. For that reasons, clindamycin-rifampin combination therapy is frequently used&#xD;
      in these infections.Clindamycin is metabolized by the P450 3A4 cytochrome, an enzyme strongly&#xD;
      inducible by rifampin. A retrospective study published in 2010 on 70 patients treated for&#xD;
      bone and joint infections showed that clindamycin serum concentrations were significantly&#xD;
      lower when clindamycin was combined with rifampin (5.3 mg/liter vs 8.9 mg/liter; p&lt;0.02).&#xD;
      This drug interaction could even be stronger with the oral route, because of hepatic&#xD;
      first-past effect, ending up with very low clindamycin serum concentration, a risk of&#xD;
      selecting resistant microorganisms and treatment failure. This latter point is an important&#xD;
      issue, because clindamycin has an excellent oral bioavailability and is frequently used in&#xD;
      oral regimens. In the above study, a wide variability of clindamycin serum concentration was&#xD;
      observed in the group of patients treated with combination therapy (1-12mg/l) suggesting&#xD;
      interindividual variability. Rifampin induction of CYP 450 3A4/A5 depends on different&#xD;
      receptor (PXR, RXR, LXRalpha) submitted to genetic polymorphism. Hypothesis: Plasma clearance&#xD;
      of clindamycin (CLclin) combined with rifampicin (CLclinrif) is higher when clindamycin is&#xD;
      administered by the oral route (CLclinrif OR) compared with IV administration (CLclinrif IV).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mean clearances of clindamycin</measure>
    <time_frame>3 weeks</time_frame>
    <description>The principal evaluation criterion is the mean clearances of clindamycin with and without administration of rifampin (intravenous or oral administration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean clearances of clindamycin</measure>
    <time_frame>5 weeks</time_frame>
    <description>The principal evaluation criterion is the mean clearances of clindamycin with and without administration of rifampin (intravenous or oral administration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma concentrations of IV- or PO-administered clindamycin, combined or not with rifampin.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma concentrations of IV- or PO-administered clindamycin, combined or not</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">49</enrollment>
  <condition>Arthritis, Infectious</condition>
  <condition>Bone Diseases, Infectious</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>usual antibiotic treatment</intervention_name>
    <description>pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients hospitalized for medical-surgical management of OAIs in the Department of Trauma&#xD;
        and Bone Surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥18 years&#xD;
&#xD;
          -  surgical management of OAI&#xD;
&#xD;
          -  Postoperative IV antibiotic therapy for 10±2 days&#xD;
&#xD;
          -  Chronic bone and/or joint infection (evolving for &gt;4 weeks) with bacteriologically&#xD;
             documented staphylococci, streptococci or susceptible anaerobes in skin flora&#xD;
             susceptible to clindamycin and rifampin&#xD;
&#xD;
          -  Continuation of IV administration possible for a maximum of 25 days&#xD;
&#xD;
          -  Patient consent to participate in the study&#xD;
&#xD;
          -  Patients entitled enrolled to a French National Health Insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or intolerance to the family of antibiotics used, i.e. lincosamides&#xD;
             (clindamycin, lincomycin) and rifamycins (rifampin), or to one of their constituents&#xD;
&#xD;
          -  Taking active products able to induce CYP3A4/3A5: alcohol (chronic intake),&#xD;
             anti-seizure drugs (carbamazepine, phenobarbital, phenytoin), anti-infectious agents&#xD;
             (rifabutin, efavirenz, nevirapine, griseofulvin), anti-fungals (ketoconazole,&#xD;
             itraconazole, voriconazole, posaconazole, fluconazole, miconazole), calcium channel&#xD;
             blockers (diltiazem, verapamil), macrolides (erythromycin, clarithromycin, josamycin,&#xD;
             telithromycin)&#xD;
&#xD;
          -  Being treated with one of the following: cyclosporine and/or tacrolimus&#xD;
             (immunosuppressants) ; midazolam (psychotropic agents)&#xD;
&#xD;
          -  Human immunodeficiency virus-positive patient being treated with protease inhibitors&#xD;
             (ritonavir, amprenavir, atazanavir, indinavir, nelfinavir, lopinavir, saquinavir) or&#xD;
             delavirdine&#xD;
&#xD;
          -  Cirrhosis, hepatocellular insufficiency&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 mL/min (according to the cockcroft and gault formula)&#xD;
&#xD;
          -  Severe sepsis (systolic blood pressure (SBP) &lt;90 mm Hg; O2 saturation &lt;90%,&#xD;
             encephalopathy, oligo-anuria, creatininemia &gt;176 mmol/L, platelets &lt;100,000/mm3, INR&#xD;
             &gt;1.5, Glasgow coma score &lt;13) or septic shock (persistent hypotension despite&#xD;
             volumetric filling) at arrival in the unit&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Congenital galactosemia, glucose and galactose malabsorption syndrome, lactase deficit&#xD;
             because of the presence of lactose in the dalacin® capsules&#xD;
&#xD;
          -  Intolerance of fructose, glucose and galactose malabsorption syndrome,&#xD;
             sucrase-isomaltase deficit because of the presence of saccharose in the rifadin®&#xD;
             capsules&#xD;
&#xD;
          -  Major cognitive disorders, according to the DSM IV-TR (Diagnostic and Statistical&#xD;
             Manual of Mental Disorders) definition (36)&#xD;
&#xD;
          -  Weight &gt;100 kg or &lt;50 kg&#xD;
&#xD;
          -  Woman of childbearing age using estrogen-progestin contraception and not wanting to&#xD;
             switch to an effective mechanical-type contraceptive method&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Patient under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>GH Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bone Diseases, Infectious</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

